Recent evidence suggests that new-onset diabetes after transplant adversely affects orthotopic liver transplant patient and graft survival.
Dr Orloff and colleagues from Oregon evaluated the effect of Hepatitis C infection on the natural history of new-onset diabetes after transplant.
The investigators conducted a retrospective review of 492 orthotopic liver transplant recipients at a single center from 1993 to 2003.
Patients were followed for a minimum of 12 months, ranging to 10 years.
The researchers reported that the study population consisted of 444 orthotopic liver transplant recipients, of which 206 were Hepatitis C positive and 238 were negative.
New-onset diabetes after transplant was defined by the need for antidiabetic medication for at least 7 days starting anytime after orthotopic liver transplant.
|The overall incidence of new-onset diabetes after transplant was 33 %|
|American Journal of Surgery|
The research team performed statistical analysis by using the Student t test, Kaplan-Meier survival, and chi-square tests.
The team noted that the overall incidence of new-onset diabetes after transplant was 33 %.
The researchers also observed that there was a significant difference in the development of new-onset diabetes after transplant between the Hepatitis C-positive group at 40 % and the Hepatitis C-negative group at 27 %.
Other independent risk factors for development of new-onset diabetes after transplant were male gender and being more than 50 years of age.
Dr Orloff’s team concluded, “Hepatitis C infection contributes to the development of diabetes mellitus in orthotopic liver transplant recipients.”
“The mechanisms behind Hepatitis C infection and associated new-onset diabetes after transplant in Hepatitis C-positive orthotopic liver transplant recipients warrant further investigation.”